Schwarz' Parcopa Clears FDA For Parkinson's Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to launch carbidopa/levodopa rapid dissolve formulation Parcopa Sept. 27 with 40-person sales force. Schwarz hopes that Parcopa will help broaden the company's U.S. presence.
You may also be interested in...
Schwarz Neupro Parkinson’s Patch Is Firm’s First Attempt At New Drug Market
Generic firm announces submission of U.S. and EU applications for novel Parkinson’s disease product. NDA is based on studies in early-stage PD. NDA for late-stage PD is expected in first quarter 2006, partner Aderis says.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.